Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Wall Street researchers utilized Claude to design drug candidates, validating long-standing claims that artificial intelligence can revolutionize medical research and drug development. This experiment has generated a new investment thesis, as AI-driven design accelerates the discovery of candidates. Consequently, the industry focus is shifting toward lab testing, which is increasing the demand for experimental validation services to verify these AI-generated results in real-world laboratory settings to ensure efficacy and safety.